semaglutide blue cross IBX parent company posts $239M financial loss does anthem blue cross blue

Key Takeaways Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) across both clinical trials and the first direct head-to-head comparison, 20.9% versus 14.9% in separate Phase 3 trials, and 20.2% versus 13.7% in the SURMOUNT-5 trial published in the New England Journal of Medicine

If someone has a history of restrictive eating, they are someone who should not take GLP-1 drugs

However, autophagosome markers are decreased which may indicate there was a defect in the removal of mitochondria fragments, while reduced mitophagy markers may indicate that there were less healthy mitochondria fragments to be recycled

Time matters most of all